Improving CRISPR-Cas9 Gene Editing Using HDAC Inhibitors and Designed Virus-Like Particles

FAME-CRISPR increased CRISPR-Cas9 editing efficiency by combining pan-HDAC inhibition with engineered virus-like particle delivery.

This platform experiment tested pan-HDAC inhibitor treatment with eVLP transduction for DSB-mediated CRISPR and base editing in immortalized cancer cells and primary diploid fibroblasts, reporting 4-fold higher efficiency and edited populations within 2- to 3-cell mean population doublings.

The evidence is limited to cell-model editing performance and does not establish in vivo delivery, safety, or therapeutic efficacy.